- Report
- December 2018
- 30 Pages
China
From €2115EUR$2,200USD£1,813GBP
- Report
- March 2021
- 149 Pages
Global
From €3460EUR$3,600USD£2,967GBP
- Report
- March 2021
- 72 Pages
Middle East, Africa
From €1442EUR$1,500USD£1,236GBP
- Report
- February 2021
- 225 Pages
Global
From €5545EUR$5,769USD£4,755GBP
Micardis is a brand of telmisartan, an angiotensin II receptor blocker (ARB) used to treat hypertension and reduce the risk of cardiovascular events. It is also used to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. It is available in tablet form and is taken orally. It is usually taken once a day, with or without food.
Micardis is part of a larger market of cardiovascular drugs, which are used to treat a variety of conditions related to the heart and blood vessels. These drugs include beta blockers, ACE inhibitors, calcium channel blockers, and diuretics. They are used to treat high blood pressure, angina, heart failure, and other conditions.
The market for cardiovascular drugs is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies include AstraZeneca, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more